Journal article
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
EA Joura, AR Giuliano, OE Iversen, C Bouchard, C Mao, J Mehlsen, ED Moreira, Y Ngan, LK Petersen, E Lazcano-Ponce, P Pitisuttithum, JA Restrepo, G Stuart, L Woelber, YC Yang, J Cuzick, SM Garland, W Huh, SK Kjaer, OM Bautista Show all
New England Journal of Medicine | Published : 2014
Abstract
BACKGROUND: The investigational 9-valent viruslike particle vaccine against human papillomavirus (HPV) includes the HPV types in the quadrivalent HPV (qHPV) vaccine (6, 11, 16, and 18) and five additional oncogenic types (31, 33, 45, 52, and 58). Here we present the results of a study of the efficacy and immunogenicity of the 9vHPV vaccine in women 16 to 26 years of age. METHODS: We performed a randomized, international, double-blind, phase 2b-3 study of the 9vHPV vaccine in 14,215 women. Participants received the 9vHPV vaccine or the qHPV vaccine in a series of three intramuscular injections on day 1 and at months 2 and 6. Serum was collected for analysis of antibody responses. Swabs of lab..
View full abstractGrants
Funding Acknowledgements
Funded by Merck; ClinicalTrials.gov number, NCT00543543